Steven Leonard Chapman Sells 13,685 Shares of Natera, Inc. (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA) CEO Steven Leonard Chapman sold 13,685 shares of the stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $165.87, for a total transaction of $2,269,930.95. Following the completion of the sale, the chief executive officer now owns 253,944 shares in the company, valued at approximately $42,121,691.28. This trade represents a 5.11 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Steven Leonard Chapman also recently made the following trade(s):

• On Wednesday, January 22nd, Steven Leonard Chapman sold 78,553 shares of Natera stock. The stock was sold at an average price of $164.97, for a total transaction of $12,958,888.41.
• On Friday, November 15th, Steven Leonard Chapman sold 4,728 shares of Natera stock. The shares were sold at an average price of $146.41, for a total value of $692,226.48.

Natera Stock Performance

Shares of NTRA stock opened at $176.92 on Monday. The firm has a market cap of $23.36 billion, a price-to-earnings ratio of -100.52 and a beta of 1.65. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.23 and a current ratio of 4.39. Natera, Inc. has a 52 week low of $64.74 and a 52 week high of $183.00. The firm’s 50-day simple moving average is $166.89 and its two-hundred day simple moving average is $138.50.

Natera (NASDAQ:NTRA) last posted its quarterly earnings results on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.57) by $0.31. The company had revenue of $439.80 million for the quarter, compared to analyst estimates of $361.43 million. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The company’s quarterly revenue was up 63.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.95) earnings per share. As a group, equities analysts forecast that Natera, Inc. will post -1.56 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts have weighed in on the company. Piper Sandler boosted their price target on Natera from $150.00 to $200.00 and gave the stock an “overweight” rating in a research report on Monday, November 18th. Morgan Stanley lifted their target price on Natera from $132.00 to $176.00 and gave the company an “overweight” rating in a research report on Thursday, November 14th. Robert W. Baird lifted their price target on Natera from $120.00 to $160.00 and gave the company an “outperform” rating in a research note on Wednesday, November 13th. JPMorgan Chase & Co. lifted their price objective on Natera from $160.00 to $200.00 and gave the stock an “overweight” rating in a research note on Friday, December 13th. Finally, Leerink Partners lifted their target price on Natera from $140.00 to $150.00 and gave the stock an “outperform” rating in a report on Thursday, October 17th. One investment analyst has rated the stock with a sell rating and seventeen have issued a buy rating to the stock. According to MarketBeat, Natera presently has an average rating of “Moderate Buy” and an average target price of $165.88.

Institutional Trading of Natera

A number of hedge funds and other institutional investors have recently bought and sold shares of NTRA. Blue Trust Inc. increased its holdings in Natera by 104.3% during the 4th quarter. Blue Trust Inc. now owns 190 shares of the medical research company’s stock worth $30,000 after acquiring an additional 97 shares during the period. Quarry LP increased its holdings in shares of Natera by 148.4% in the second quarter. Quarry LP now owns 318 shares of the medical research company’s stock worth $34,000 after buying an additional 190 shares during the period. Versant Capital Management Inc lifted its position in Natera by 345.8% in the fourth quarter. Versant Capital Management Inc now owns 214 shares of the medical research company’s stock valued at $34,000 after purchasing an additional 166 shares during the last quarter. Covestor Ltd boosted its position in Natera by 34.3% during the 3rd quarter. Covestor Ltd now owns 372 shares of the medical research company’s stock valued at $47,000 after buying an additional 95 shares during the period. Finally, Principal Securities Inc. boosted its holdings in shares of Natera by 20.7% during the fourth quarter. Principal Securities Inc. now owns 344 shares of the medical research company’s stock worth $54,000 after purchasing an additional 59 shares during the period. Institutional investors own 99.90% of the company’s stock.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.